REG - RTW Biotech Opp. - New Investment in Series A of Ottimo Pharma

RTW Biotech OpportunitiesAnnouncement

20/12/2024 12:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241220:nRST9727Qa&default-theme=true

RNS Number : 9727Q  RTW Biotech Opportunities Ltd  20 December 2024

LEI: 549300Q7EXQQH6KF7Z84

20 December 2024

RTW Biotech Opportunities Ltd

New Investment in Series A of Ottimo Pharma

RTW Biotech Opportunities Ltd (the "Company"), a London Stock Exchange-listed
investment company focused on identifying transformative assets with high
growth potential across the life sciences sector, is pleased to note a new
portfolio company investment in Ottimo Pharma ("Ottimo"), a company pioneering
bifunctional medicines to extend the lives of people living with cancer.
Ottimo announced the completion of its Series A financing round of over $140
million. The financing will accelerate the lead asset, Jankistomig, a
first-in-class PD1/VEGFR2 bifunctional antibody for multiple solid tumour
indications, and a pipeline of follow-on bifunctional assets. The Company
participated in the Series A alongside other investment vehicles managed
by RTW Investments, LP (the "Investment Manager").

 

Ottimo Pharma is a private biotechnology company focused on the development of
pioneering innovative cancer therapies for solid tumours. Jankistomig is
designed as a dual pathway, biparatopic single-agent IgG therapy, targeting
both immune checkpoint inhibition and angiogenesis in the treatment of cancer.
By advancing this dual-pathway approach, Ottimo aims to offer a wider
therapeutic window, improve cancer treatment outcomes and reduce the overall
healthcare burden.

 

Roderick Wong, Managing Partner and CIO at the Investment Manager said, "We
are thrilled to support Ottimo Pharma at this pivotal juncture. The innovative
approach and promising potential of Jankistomig align with our mission to
invest in transformative healthcare solutions. We believe Ottimo's
bifunctional antibody approach holds significant promise for addressing unmet
needs in oncology, and we look forward to contributing to their continued
success."

The full text of the announcement can be accessed at https://ottimopharma.com
(https://ottimopharma.com/ottimo-pharma-raises-over-140-million-in-series-a-financing/)
.

 

  For Further Information

 RTW Investments, LP                                                      +44 20 7959 6361
 Woody Stileman, Managing Director, Business Development                  biotechopportunities@rtwfunds.com (mailto:biotechopportunities@rtwfunds.com)

 Krisha McCune, Director, Investor Relations

 Cadarn Capital (PR & Communications/Distribution & IR Partner)           +44 79 8418 4461
                                                                           Lucy@cadarncapital.com (mailto:Lucy@cadarncapital.com)

 Lucy Clark (PR)

 David Harris (Distribution)                                              +44 73 6888 3211

                                                                          david@cadarncapital.com

 Deutsche Numis (Joint Corporate Broker)                                  +44 20 7260 1000

 Freddie Barnfield

 Nathan Brown

 Euan Brown

 BofA Securities (Joint Corporate Broker)                                 +44 20 7628 1000

 Edward Peel

 Alex Penney

 Elysium Fund Management Limited                                           +44 14 8170 3100

 Joanna Duquemin Nicolle, Chief Executive Officer

 Sadie Morrison, Managing Director

 Morgan Stanley Fund Services USA LLC                                     +1 914 225 8885

 

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

***********

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAAAEAEFLFFA